查詢結果分析
相關文獻
- Treatment of Cerebral Palsy with Botulinum Toxin: Evaluation with Gross Motor Function Measure
- 肉毒桿菌毒素處理痙攣型腦性麻痺的成效
- 肉毒桿菌毒素治療兒童腦性麻痺患者流口水障礙之初步報告
- 肉毒桿菌毒素治療腦性麻痺兒童痙攣之臨床成效
- Botulinum Toxin Type A Treatment for Drooling in Taiwanese Children with Cerebral Palsy: Three Case Reports
- Botulinum Toxin A in the Treatment of Sialorrhea in Children with Cerebral Palsy
- 結合A型肉毒桿菌毒素注射與改良式侷限誘發動作治療於痙攣型半側偏癱腦性麻痺臺灣兒童之療效:病例報告
- 極低出生體重早產兒造成腦性麻痺的危險因子之探討
- 腦性麻痺導致髖關節脫臼之臨床探討
- 選擇性背神經根切斷術對腦性麻痺病童步態之成效
頁籤選單縮合
題 名 | Treatment of Cerebral Palsy with Botulinum Toxin: Evaluation with Gross Motor Function Measure=以肉毒桿菌毒素治療腦性麻痺患者成效的評估 |
---|---|
作 者 | 楊翠芬; 詹瑞棋; 莊天佑; 劉作仁; 邱然偉; | 書刊名 | 臺灣醫學會雜誌 |
卷 期 | 98:12 1999.12[民88.12] |
頁 次 | 頁832-836 |
分類號 | 418.294 |
關鍵詞 | 肉毒桿菌毒素; 腦性麻痺; Cerebral palsy; Botulinum toxin A; Spasticity; |
語 文 | 英文(English) |
英文摘要 | The objective of this study was to investigate the effects of botulinum toxin A (BTA) injection in reducing muscular spasticity and improving locomotor function in children with cerebral palsy. Thirty-eight children with spastic cerebral palsy who were undergoing regular physical theraphy were enrolled. Twenty-eight of these received BTA injection at the hip adductors and/or gastrocnemius, while the other 10, whose parents refused the BTA treatment protocol, served as the comparison group. The main outcome measures were:improvements in the severity of spasticity, walking distance, gross motor function (as assessed with the Gross Motor Function Measure, GMFM), and gait pattern (as assessed with the Physician Rating Scale, PRS), all measured 6 and 12 weeks after the start of BTA treatment. The severity of spasticity and walking distance at baseline did not differ significantly between the two groups. However, the severity of spasticity improved markedly in the BTA group, from 2.7 to 1.5 (Modified Ashworth Scale) at the hip adductor, and from 2.9 to 1.9 at the gastrocnemius at the 6-week follow-up. The walking distance improved from 46.17 m to 55.32 m at the 6-week follow-up, and to 66.6 m at the 12-week follow-up in the BTA group. Marked improvemtns in the quality of several gross motor functions were also noted in the BTA group. The improvements in spasticity, walking distance, and gross motor function were significantly greater in the BTA group than in the comparison group. The improvements in gait pattern did not differ significantly between the BTA and comparison groups. The findings of this study show BTA injection to be an effective treatment for reducing spasticity and improving gross motor function in children with spastic cerebral palsy. GMFM provides objective evidence regarding functional improvement after treatment in this patient population. |
本系統中英文摘要資訊取自各篇刊載內容。